Best Immunotherapy Companies in Washington, United States
The 40 best Immunotherapy companies in Washington, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Umoja Biopharma.
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Washington
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Umoja Biopharma Developer of cancer therapeutics | $263M | 19 mo ago | 168 | Michael Jensen Co-Founder | WordPressMySQLPHP+18 | Top 5M | 132 patents Lentiviral vector manufacturing and engineered stem cell therapies for immuno‑oncology | — |
| 2 | Profound Bio Developer of novel therapies for the treatment of cancer | $250M | 30 mo ago | — | Baiteng Zhao CEO | — | — | — | — |
| 3 | CytoDyn Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection 32Funding top 17%Growth top 35%Patents top 36%Innovation top 44% All 10 signals ▾Fundingtop 17% Growthtop 35% Patentstop 36% Innovationtop 44% Moatbottom 49% Globalbottom 36% Techbottom 35% Newsbottom 26% Marketbottom 25% Fin. healthbottom 24% Funding: Raised $250M across 23 rounds · 23 rounds over 17 yrs (1.4/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 32/100 | $250M | 6 mo ago | 12 12 → 23 (+92%) | — | Apple iCloud MailMicrosoft 365Bootstrap+8 | Top 5M | 107 patents CCR5-targeted biologics for HIV, cancer, inflammation, and NAFLD/NASH therapies | 1 partnership |
| 4 | Silverback Therapeutics Stealth mode immuno-oncology biotech startup | $211M | 71 mo ago | 17 | Peter Thompson Co-Founder | — | — | 143 patents Develops small‑molecule kinase inhibitors and antibody‑drug conjugates for oncology targets. | — |
| 5 | Outpace Bio Developer of T-cell therapies for cancer treatment | $200M | 25 mo ago | 48 48 → 73 (+52%) | Scott Boyken Co-Founder | — | Top 10M | — | — |
| 6 | Callio Therapeutics Developer of multi-payload antibody-drug conjugates for cancer treatment | $187M | 18 mo ago | — | Jerome Kirkup Co-Founder & Chief Scientific Officer | — | — | — | — |
| 7 | OncoResponse Developer of immunotherapies for the treatment of cancer 64Funding top 20%Moat top 21%Patents top 24%Innovation top 27% All 8 signals ▾Fundingtop 20% Moattop 21% Patentstop 24% Innovationtop 27% Growthtop 28% Talentbottom 49% Globalbottom 42% Marketbottom 38% Funding: Raised $144M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 56 patents rank vs industry peers · Fliar Intelligence Index 64/100 | $144M | 16 mo ago | 33 | Clifford Stocks Founder & CEO | — | — | 56 patents LILRB2 immune‑checkpoint antibodies for cancer immunotherapy | — |
| 8 | Just Biotherapeutics Designing technologies to accelerate biotherapeutic development and to reduce manufacturing costs | $124M | 99 mo ago | 79 | — | — | — | 36 patents Protein structure prediction, purification optimization, and high‑throughput physico‑chemical profiling | — |
| 9 | VentiRx Developing small molecule product candidates targeting Toll-like receptor 8 (TLR8) for cancer | $120M | 143 mo ago | 15 | — | — | — | — | — |
| 10 | Alder Biopharmaceuticals Humanized monoclonal antibody based therapeutics for migraine and inflammatory diseases | $105M | 102 mo ago | 202 | — | — | — | 313 patents Patents concentrated in chemistry & materials | — |
| 11 | Kineta Developing immune-modulating therapeutics and vaccine adjuvants for autoimmune and infectious diseases | $104M | 50 mo ago | 12 | — | — | — | 217 patents Patents concentrated in chemistry & materials | — |
| 12 | immune design Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases. | $101M | 147 mo ago | 50 | — | — | — | 256 patents Engineered viral vectors for cancer immunotherapy delivering cytokine and replicon RNA | — |
| 13 | Bonum Therapeutics Manufacturer of cytokine based drugs 45Funding top 22%Talent bottom 49%Tech bottom 45%Global bottom 43% All 5 signals ▾Fundingtop 22% Talentbottom 49% Techbottom 45% Globalbottom 43% Marketbottom 36% Funding: Raised $93.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 45/100 | $93M | 5 mo ago | 54 | John Mulligan Founder & CEO | WordPressMySQLPHP+21 | Top 50M | — | — |
| 14 | Curevo Developer of vaccines for the treatment of various diseases 29Funding top 25%Talent top 41%Moat top 43%Patents top 48% All 9 signals ▾Fundingtop 25% Talenttop 41% Moattop 43% Patentstop 48% Techtop 50% Innovationbottom 45% Globalbottom 39% Marketbottom 22% Newsbottom 18% Funding: Raised $86.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Talent: Analyst team rating 4/5 · 1 named leader on record rank vs industry peers · Fliar Intelligence Index 29/100 | $86M | 18 mo ago | 8 | George Simeon CEO | WordPress Block EditorElementorWordPress+29 | Top 50M | 3 patents Herpes zoster immunogenic vaccine formulations and combination vaccine technologies. | — |
| 15 | Theraclone Sciences Discovering human monoclonal antibodies for safe and effective therapeutic product development | $61M | 136 mo ago | 19 | Clifford J Stocks CEO | — | — | 225 patents Broadly neutralizing monoclonal antibodies targeting HIV-1 envelope glycoprotein (gp120/gp41) | — |
| 16 | VLST Corporation Online slot gaming site with high RTP and maxwin opportunities | $60M | 242 mo ago | 13 | Craig Smith Founder | — | — | 10 patents Therapeutic antibodies that neutralize multiple CC chemokines for immune modulation | — |
| 17 | Aptevo Therapeutics Developing T-cell cytotoxicity targeted immunotherapeutic drugs primarily for cancer and hematology | $57M | 17 mo ago | 45 45 → 56 (+24%) | Marvin White President and CEO | WordPressMySQLPHP+18 | Top 10M | — | — |
| 18 | Immusoft Developer of programmed B cell therapies for protein delivery | $44M | 27 mo ago | 20 | Matthew Scholz Founder | — | — | 66 patents Engineered B cells as living factories for therapeutic protein delivery and disease modulation | — |
| 19 | Allozyne Protein therapeutics for CNS diseases such as multiple sclerosis. | $40M | 156 mo ago | 6 | Dee Datta Ex-Co-Founder | — | — | 39 patents Engineered eukaryotic cell lines and synthetic non‑natural amino acid/nucleic acid technologies | — |
| 20 | Good Therapeutics Developer of protein-based drugs for cancer | $37M | 56 mo ago | 23 | — | — | — | — | — |
| 21 | HDT Bio Developer of immunotherapy for the treatment of cancer & infectious diseases | $31M | 15 mo ago | 32 32 → 54 (+69%) | — | WordPressApple iCloud MailMicrosoft 365+21 | Top 50M | — | — |
| 22 | Etubics Therapeutic vaccines for cancer | $23M | 143 mo ago | 14 | — | — | — | 160 patents Viral vector production platforms for multi‑antigen vaccines and cancer immunotherapy | — |
| 23 | Aminex Therapeutics Immuno-oncology company developing novel therapies to empower the immune system | $21M | 46 mo ago | 9 | — | — | — | — | — |
| 24 | Link Immunotherapeutics Developer of immunotherapeutics to treat cancer | $14M | 64 mo ago | 15 | — | — | — | — | — |
| 25 | Orlance Developer of a platform to deliver nucleic acid vaccines and related therapies | $14M | 16 mo ago | — | Kristyn Aalto CEO | — | — | 5 patents Injectable medical drug delivery devices and associated delivery mechanisms | — |
| 26 | Tria Bioscience Innovating hearing technology for biomedical equipment manufacturers worldwide | $9M | 95 mo ago | — | Christopher Clegg Founder & President | — | — | — | — |
| 27 | Neoleukin Therapeutics Manufacturers of therapeutic proteins to treat immunological disorders | $5M | 186 mo ago | 7 | Jonathan Drachman CEO & President | — | — | — | — |
| 28 | Abacus Bioscience Developer of immunotherapeutics for treating cancer and viral diseases | $4M | 43 mo ago | 7 | Edward Clark Founder and Chair | GoDaddy Website BuilderReactRequireJS+6 | Top 50M | — | — |
| 29 | Inventprise Developer of conjugate vaccines designed to prevent infectious diseases globally | $4M | 57 mo ago | 88 88 → 105 (+19%) | Subhash Kapre Founder | WordPress Block EditorElementorWordPress+24 | Top 50M | 138 patents Advanced conjugate vaccine design and PEGylated polysaccharide adjuvant technologies | — |
| 30 | CisThera Early-stage drug development company developing therapeutics for cancer, autoimmune diseases, chronic kidney… | $2M | 192 mo ago | — | Don Staunton CEO | — | — | 12 patents Therapeutic biologics targeting BCL2 apoptosis regulators and PAI‑1 inhibition. | — |
| 31 | Canzxbio Manufacturer of immunotherapy for cancer | $1M | 83 mo ago | 4 | Jennifer Wu Founder & President | — | — | — | — |
| 32 | Alpine Immune Sciences Developer of immunotherapies to treat cancer and autoimmune disorders | $1M | 59 mo ago | 126 | — | — | — | 330 patents Engineered ICOS ligand protein therapeutics for immune modulation in cancer treatment | — |
| 33 | MalarVx Developing innovative malaria vaccines using RNA technology and in vitro culture systems | $1M | 71 mo ago | 5 | — | — | — | 3 patents Malaria vaccine formulations and delivery devices for sterile protection. | — |
Top 12 Immunotherapy companies in Washington
#1
Public · Vancouver, Washington · founded 2002 · 12 employees$249.7Mraised▾
Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection. It offers lead candidate, PRO 140,for HIV with demonstrated antiviral activity in men. PRO 140 blocks the HIV co-receptor CCR5 on T-cells that prevent viral entry.
- Mar 2026Post IPO$17.5M
- Jan 2026Post IPO$18.6M
- Apr 2022Post IPO$1.9M
- Dec 2021Post IPO$11.4M
#2
Series B · Seattle, Washington · founded 2021 · 54 employees$93Mraised▾
Manufacturer of cytokine based drugs
- Apr 2026Series B$26.9M
- Nov 2022Series A$93M
#3
Series D · Seattle, Washington · founded 2015 · 33 employees$143.6Mraised▾
Developer of immunotherapies for the treatment of cancer. The company uses a proprietary technology platform to discover human antibodies and an immune checkpoint inhibitor (CPI). The company’s lead candidate is OR2805 for the treatment of multiple tumor types.
- Apr 2025Series D$6M
- May 2023Grant (prize money)$13M
- May 2023Series D$14M
- Feb 2022Conventional Debt$50M
#4
Series C · Seattle, Washington · founded 2019 · 168 employees$263Mraised▾
Developer of cancer therapeutics. The company has developed in vivo cellular immunotherapy platform that uses gene therapy to target and attack cancer cells. The company's products include VivoVec that acts through the body’s lymphatic system, to produce cancer-fighting VivoCAR T cells. The company's proprietary RACR/CAR system is used to enhance the activity of VivoCAR T cells. The company's other product includes TumorTag which is used to tag targeted tumor cells/stromal elements.
- Jan 2025Series C$100M
- Jun 2021Series B$210M
- Nov 2020Series A$53M
#5
Series A · Seattle, Washington · founded 2024$187Mraised▾
Developer of multi-payload antibody-drug conjugates for cancer treatment. It develops next-generation antibody-drug conjugates (ADCs) with differentiated payload and linker technologies. This targeted delivery of drug combinations to tumor cells aims to maximize therapeutic benefit for cancer patients. A key focus is on HER2-targeted dual-payload ADCs, and the company is advancing these through clinical proof-of-concept. Research and early development leverage systems biology approaches. Clinical development programs are managed from initial design through to global regulatory approvals. Business development activities include partnerships across multiple therapeutic areas and modalities.
- Mar 2025Series A$187M
#6
Series B · Seattle, Washington · founded 2017 · 8 employees$86Mraised▾
Developer of vaccines for the treatment of various diseases. The company's product pipeline includes CRV-101, for Herpes Zoster, CRV0-102 used against chicken pox. Other products of the company include CRV-201 used against the respiratory syncytial virus.
- Mar 2025Series B$110M
- Nov 2022Series A$26M
- Jan 2022Series A$60M
#7
Seed · Seattle, Washington · founded 2018 · 32 employees$30.6Mraised▾
HDT Bio is a developer of immunotherapy for the treatment of cancer & infectious diseases. It enhances the body's immunity power to fight against cancer disease. It increases tumor junctions and improves the disruptive capability. It helps in the tumor penetrance and therefore improves the efficacy, of diverse therapeutics including chemotherapeutics like Paclitaxel, Doxil, Cisplatin, antibodies, oncolytic viruses, and cell therapies. It helps in the treatment of breast cancer, ovarian cancer, and many more. It also provides solutions for pathogen agnostic therapeutics that offer solutions against gram-positive and gram-negative bacteria.
- May 2025Grant (prize money)$2.7M
- May 2025Grant (prize money)$1.6M
- May 2025Grant (prize money)$2.2M
- Apr 2025Grant (prize money)$2M
#8
Public · Seattle, Washington · founded 2016 · 45 employees$57.1Mraised▾
Developing T-cell cytotoxicity targeted immunotherapeutic drugs primarily for cancer and hematology. It is using its proprietary Adaptir platform technology to develop immuno-oncology candidates that focus on redirected T-cell cytotoxicity. It generate immunotherapeutics with mechanisms of action including targeted cytokine delivery, targeting two cell surface receptors or neutralization of multiple soluble proteins. Its pipeline has 4 oncology candidates with the lead Otlertuzumab which induces cell death of primary CLL cells-B-cell tumor lines and also induces NK-cell mediated ADCC and macrophage-mediated phagocytosis for chronic lymphocytic leukemia (CLL).
- Apr 2025Post IPO$2.1M
- Jan 2017Venture Debt$20M
- Aug 2016Conventional Debt$35M
#9
Funding Raised · Seattle, Washington · founded 2016$14Mraised▾
Developer of a platform to deliver nucleic acid vaccines and related therapies. it offers MACH-1 a powdered, needle-free nucleic acid vaccines with its epidermal vaccine delivery platform. It uses pressurized gas to accelerate microparticles of vaccines.
- Apr 2025Grant (prize money)$600K
- Apr 2025Grant (prize money)$400K
- May 2024Grant (prize money)$300K
- Sep 2023Grant (prize money)$400K
#10
Series B · Seattle, Washington · founded 2020 · 48 employees$200Mraised▾
Developer of T-cell therapies for cancer treatment. The therapies include cell therapy producing controlled Cytokine X, CAR with counter- exhaustion mechanism, cell therapy producing controlled Cytokine Y, and drug-induced gene regulation. These therapies are developed by combining protein design and cell engineering and also with the help of protein design software that custom designs the new biological functions.
- Jul 2024Series B$144M
- Mar 2021Series A$30M
#11
Acquired · Woodinville, Washington · founded 2018$250Mraised▾
Developer of novel therapies for the treatment of cancer. The company is involved in the development of CMC for antibody-drug conjugates that kill tumor cells, promote cell rejuvenation, stimulates collagen production and prevents collagen degrading, and more.
- Feb 2024Series B$112M
- Jun 2022Series A$70M
- Jul 2021Series A$55M
#12
Series B · Seattle, Washington · founded 2009 · 20 employees$44.1Mraised▾
Developer of programmed B cell therapies for protein delivery. It programs B cells to function as biofactories for therapeutic protein production. The approach involves collecting a patient's B cells and programming them to produce personalized protein therapeutics. These programmed cells are then expanded and infused back into the patient, where they are expected to reside and continuously produce therapeutic proteins.
- May 2024Series B$4.6M
- Jan 2023Grant (prize money)$8M
- Nov 2021Grant (prize money)$4M
- Mar 2021Series B$10.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Immunology in Washington is moving
A read on the academic research around Immunology in Washington — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 333 papers.
- Washington University in St. Louis141
- University of Washington125
- George Washington University39
- University of Washington Medical Center12
- MedStar Washington Hospital Center7
- Immune system5→31
- Immunotherapy4→29
- Cytotoxic T cell2→15
- Tumor microenvironment1→11
- Cancer2→12
- Immune system9→41
- Immunotherapy12→41
- Cancer4→17
- Cytotoxic T cell1→13
- Chimeric antigen receptor3→12
- Immune system2→18
- Immunotherapy4→20
- Cancer2→12
- Cancer research1→5
- Chimeric antigen receptor2→5
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.